These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 29491261)
1. Fragment-Based Discovery of Pyrimido[1,2-b]indazole PDE10A Inhibitors. Chino A; Seo R; Amano Y; Namatame I; Hamaguchi W; Honbou K; Mihara T; Yamazaki M; Tomishima M; Masuda N Chem Pharm Bull (Tokyo); 2018; 66(3):286-294. PubMed ID: 29491261 [TBL] [Abstract][Full Text] [Related]
2. Discovery of 2-[(E)-2-(7-Fluoro-3-methylquinoxalin-2-yl)vinyl]-6-pyrrolidin-1-yl-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-4-amine Hydrochloride as a Highly Selective PDE10A Inhibitor. Kadoh Y; Miyoshi H; Matsumura T; Tanaka Y; Hongu M; Kimura M; Takedomi K; Omori K; Kotera J; Sasaki T; Kobayashi T; Taniguchi H; Watanabe Y; Kojima K; Sakamoto T; Himiyama T; Kawanishi E Chem Pharm Bull (Tokyo); 2018; 66(3):243-250. PubMed ID: 29491258 [TBL] [Abstract][Full Text] [Related]
3. Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis. Shipe WD; Sharik SS; Barrow JC; McGaughey GB; Theberge CR; Uslaner JM; Yan Y; Renger JJ; Smith SM; Coleman PJ; Cox CD J Med Chem; 2015 Oct; 58(19):7888-94. PubMed ID: 26378882 [TBL] [Abstract][Full Text] [Related]
4. Fragment-assisted hit investigation involving integrated HTS and fragment screening: Application to the identification of phosphodiesterase 10A (PDE10A) inhibitors. Varnes JG; Geschwindner S; Holmquist CR; Forst J; Wang X; Dekker N; Scott CW; Tian G; Wood MW; Albert JS Bioorg Med Chem Lett; 2016 Jan; 26(1):197-202. PubMed ID: 26597534 [TBL] [Abstract][Full Text] [Related]
5. Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors. Chappie TA; Humphrey JM; Allen MP; Estep KG; Fox CB; Lebel LA; Liras S; Marr ES; Menniti FS; Pandit J; Schmidt CJ; Tu M; Williams RD; Yang FV J Med Chem; 2007 Jan; 50(2):182-5. PubMed ID: 17228859 [TBL] [Abstract][Full Text] [Related]
6. Discovery of selective biaryl ethers as PDE10A inhibitors: improvement in potency and mitigation of Pgp-mediated efflux. Rzasa RM; Hu E; Rumfelt S; Chen N; Andrews KL; Chmait S; Falsey JR; Zhong W; Jones AD; Porter A; Louie SW; Zhao X; Treanor JJ; Allen JR Bioorg Med Chem Lett; 2012 Dec; 22(24):7371-5. PubMed ID: 23149228 [TBL] [Abstract][Full Text] [Related]
7. Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. Kunitomo J; Yoshikawa M; Fushimi M; Kawada A; Quinn JF; Oki H; Kokubo H; Kondo M; Nakashima K; Kamiguchi N; Suzuki K; Kimura H; Taniguchi T J Med Chem; 2014 Nov; 57(22):9627-43. PubMed ID: 25384088 [TBL] [Abstract][Full Text] [Related]
8. Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Raheem IT; Schreier JD; Fuerst J; Gantert L; Hostetler ED; Huszar S; Joshi A; Kandebo M; Kim SH; Li J; Ma B; McGaughey G; Sharma S; Shipe WD; Uslaner J; Vandeveer GH; Yan Y; Renger JJ; Smith SM; Coleman PJ; Cox CD Bioorg Med Chem Lett; 2016 Jan; 26(1):126-32. PubMed ID: 26602277 [TBL] [Abstract][Full Text] [Related]
9. Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia. Layton ME; Kern JC; Hartingh TJ; Shipe WD; Raheem I; Kandebo M; Hayes RP; Huszar S; Eddins D; Ma B; Fuerst J; Wollenberg GK; Li J; Fritzen J; McGaughey GB; Uslaner JM; Smith SM; Coleman PJ; Cox CD J Med Chem; 2023 Jan; 66(2):1157-1171. PubMed ID: 36624931 [TBL] [Abstract][Full Text] [Related]
10. Use of structure based design to increase selectivity of pyridyl-cinnoline phosphodiesterase 10A (PDE10A) inhibitors against phosphodiesterase 3 (PDE3). Hu E; Kunz RK; Rumfelt S; Andrews KL; Li C; Hitchcock SA; Lindstrom M; Treanor J Bioorg Med Chem Lett; 2012 Nov; 22(22):6938-42. PubMed ID: 23044369 [TBL] [Abstract][Full Text] [Related]
11. Discovery of [¹¹C]MK-8193 as a PET tracer to measure target engagement of phosphodiesterase 10A (PDE10A) inhibitors. Cox CD; Hostetler ED; Flores BA; Evelhoch JL; Fan H; Gantert L; Holahan M; Eng W; Joshi A; McGaughey G; Meng X; Purcell M; Raheem IT; Riffel K; Yan Y; Renger JJ; Smith SM; Coleman PJ Bioorg Med Chem Lett; 2015 Nov; 25(21):4893-4898. PubMed ID: 26077491 [TBL] [Abstract][Full Text] [Related]
12. Discovery of novel potent imidazo[1,2-b]pyridazine PDE10a inhibitors. Meegalla SK; Huang H; Illig CR; Parks DJ; Chen J; Lee YK; Wilson KJ; Patel SK; Cheung WS; Lu T; Kirchner T; Askari HB; Geisler J; Patch RJ; Gibbs AC; Rady B; Connelly M; Player MR Bioorg Med Chem Lett; 2016 Sep; 26(17):4216-22. PubMed ID: 27491708 [TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of a novel 2-oxindole scaffold as a highly potent and brain-penetrant phosphodiesterase 10A inhibitor. Yoshikawa M; Kamisaki H; Kunitomo J; Oki H; Kokubo H; Suzuki A; Ikemoto T; Nakashima K; Kamiguchi N; Harada A; Kimura H; Taniguchi T Bioorg Med Chem; 2015 Nov; 23(22):7138-49. PubMed ID: 26494583 [TBL] [Abstract][Full Text] [Related]
14. CoMFA and HQSAR studies on 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as phosphodiesterase10A inhibitors. Kulkarni SS; Patel MR; Talele TT Bioorg Med Chem; 2008 Apr; 16(7):3675-86. PubMed ID: 18299198 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and pharmacological evaluation of novel polycyclic heteroarene ethers as PDE10A inhibitors: Part I. Das S; Harde RL; Shelke DE; Khairatkar-Joshi N; Bajpai M; Sapalya RS; Surve HV; Gudi GS; Pattem R; Behera DB; Jadhav SB; Thomas A Bioorg Med Chem Lett; 2014 May; 24(9):2073-8. PubMed ID: 24725435 [TBL] [Abstract][Full Text] [Related]
16. Identification and optimization of PDE10A inhibitors using fragment-based screening by nanocalorimetry and X-ray crystallography. Recht MI; Sridhar V; Badger J; Bounaud PY; Logan C; Chie-Leon B; Nienaber V; Torres FE J Biomol Screen; 2014 Apr; 19(4):497-507. PubMed ID: 24375910 [TBL] [Abstract][Full Text] [Related]
17. Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors. Kehler J; Ritzen A; Langgård M; Petersen SL; Farah MM; Bundgaard C; Christoffersen CT; Nielsen J; Kilburn JP Bioorg Med Chem Lett; 2011 Jun; 21(12):3738-42. PubMed ID: 21602043 [TBL] [Abstract][Full Text] [Related]
18. BN/CC isosterism in borazaronaphthalenes towards phosphodiesterase 10A (PDE10A) inhibitors. Vlasceanu A; Jessing M; Kilburn JP Bioorg Med Chem; 2015 Aug; 23(15):4453-4461. PubMed ID: 26113188 [TBL] [Abstract][Full Text] [Related]
19. Synthesis, SAR study, and biological evaluation of novel quinoline derivatives as phosphodiesterase 10A inhibitors with reduced CYP3A4 inhibition. Hamaguchi W; Masuda N; Miyamoto S; Shiina Y; Kikuchi S; Mihara T; Moriguchi H; Fushiki H; Murakami Y; Amano Y; Honbou K; Hattori K Bioorg Med Chem; 2015 Jan; 23(2):297-313. PubMed ID: 25515954 [TBL] [Abstract][Full Text] [Related]
20. Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors. Höfgen N; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Tremmel P; Pangalos MN; Marquis KL; Hage T; Harrison BL; Malamas MS; Brandon NJ; Kronbach T J Med Chem; 2010 Jun; 53(11):4399-411. PubMed ID: 20450197 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]